|
Bladder cancer gene expression subtypes (60 gene signature) to define prognosis, differential immune response, and biomarker associations. |
| |
|
No Relationships to Disclose |
| |
|
|
| |
|
|
| |
|
Leadership - Bioclassifier; GeneCentric |
Stock and Other Ownership Interests - Bioclassifier; GeneCentric |
Consulting or Advisory Role - Bioclassifier; G1 Therapeutics; GeneCentric; Ions Pharmaceuticals |
Patents, Royalties, Other Intellectual Property - royalties from PAM50 breast cancer gene patent application, and from lung gene signature patent |
| |
|
|
Stock and Other Ownership Interests - GeneCentric |
Consulting or Advisory Role - GeneCentric |
Patents, Royalties, Other Intellectual Property - I hold several diagnostic patents or pending patents in the area of solid tumor diagnostics |
| |
|
|
|
Stock and Other Ownership Interests - GeneCentric |
| |
|
|
|
Stock and Other Ownership Interests - GeneCentric |